

Notes of the Formulary Management Group

Held on	Tuesday 4 th June 2019			12:30pm (2:30pm finish) at Jubilee House, Board Room	
Members	Attended	Apologies	Absent	Designation	Abbreviation
	√			Head of Medicines Management	(C)
	√			Prescribing Adviser	(PA)
	√			Prescribing Adviser	(PA2)
	√			Lead Formulary Pharmacist	(FP)
	√			GP Lead for Medicines Management	(GP)
	√			Primary Care Pharmacist	(PCP)
			√	Clinical Nurse Specialist	(CNS)
			√	Nurse Non-Medical Prescriber	(NNMP)
		√		DWMHCP Chief Pharmacist	(DWMHCP)
			√	Patient Representative	(PR)
			√	LMC Representative	(LMC)
		√		Quality & Safety Officer	(QSO)
	√			Medicines Optimisation Pharmacist	(MOP)
	√			Commissioning Administrator/Minute Taker	(CA)

	Agenda item	Action
1.	<p><u>Welcome and Apologies (Declarations of AOB)</u></p> <p>Apologies from QSO and DWMHCP. C welcomed everyone to the meeting, advising that this was not quorate – however, as there were no applications for ratification, being non quorate would be accepted for this meeting. Medicines Optimisation Pharmacist attended the end of the meeting to support guidelines discussion (MOP).</p>	
2.	<p><u>Minutes of the Last Meeting</u></p> <p>A few spelling errors were noted, along with confirmation of whom the actions were assigned to. Following the appropriate amendments discussed at the meeting, C is happy to sign these off. PCP entered the meeting at 12:45pm</p>	
3.	<p><u>Matters Arising/Actions Sheet</u></p> <ul style="list-style-type: none"> • Clearfilm and Acticoat flex 3 - Complete • Semaglutide stabilisation - Complete • Tapentadol risk to be uploaded on to Optimise - Complete • FP10 prescribing of Semaglutide - Complete • GP comments on applications received - Complete • 365 Non-woven Island Dressing Application - Complete • Venlafaxine Application - Complete • FIASP Application - Complete • Fast Track System - Complete • UCS Wipes - Complete • Dementia Drugs Shared Care Agreement - Complete • Net Formulary - Complete <p>Remaining actions to stay on the log as these have not yet been completed.</p>	
4.	<p><u>Declarations of Interest (DOI) – Check Compliance</u></p>	

Notes of the Formulary Management Group

	Reminders were given by the C to complete their DOI forms.	
5.	<p><u>Non NICE TA Drug/devices - Full Applications</u></p> <p>Currently, we do not have any applications this month. FP gave a brief update on Dacepton. However, there was no formal application for this, so no decisions could be made. It was advised that this works out cheaper to use and has been suggested by Geriatric consultant. More applications are available when using Dacepton and lasts for two weeks. FP advised that the costs saving per patient is substantial and more costs effective for the CCG and Primary Care. Geriatric consultant would need to write a patient letter to GP to advise of dosage.</p>	
6.	<p><u>Trust Formulary Updates - Hospital only applications. For information only.</u></p> <p>FP provided updates for the committee, asked the committee to read these updates. C mentioned that this includes Self Care and OTC posters – it was asked if the Trust would be displaying these posters. Discussions were had around the OTC products and the costs surrounding this. Exposure is required around the OTC Policy within the Trust. Action: FP to provide more information on this to C. Also to list the activities that have been completed for this campaign and send to C.</p>	
7.	<p><u>NICE Technology Appraisal</u></p> <p>FP to continue sending this to the committee. Work is currently ongoing with this and the committee have viewed for April 2019.</p>	
8.	<p><u>Pathway/Guidelines</u></p> <p><u>Respiratory COPD Guidelines</u> – PA2 advised that this is currently being updated and is the first item being looked at during the right care programme. There is a respiratory STP launch of COPD inhaler options across Dudley, Walsall, Sandwell and Wolverhampton. We would still be required to have our own guidelines within each of the CCG's, but will be cascaded to all in Walsall on 19th June. Guidance is for inhaler prescribing for new patients. Action: Respiratory consultant has been requested to attend the July FMG meeting to discuss further. Action: FP to look into an Asthma Support Colleague within the Trust, for further supporting collaborative working in updating these asthma guidelines</p> <p><u>Palliative Guidelines</u> – FP advised that this is going to be brought to July's FMG meeting. Confirmed that this is the final version and that it has been passed. Action: FP to gain the final version of the document and brought to July FMG. Action: To be added to Net-Formulary website once final version received. Action: A separate tab for 'St Giles' to be created by PA2 once final version has been received.</p> <p><u>Summary Care Sheet</u> – C has suggested a cover sheet to be included with submissions to FMG, in order to include brief information in relation to what is expected from the committee and the action they would like to be taken. It was asked if this should be implemented within the FMG meeting. Action: C to prepare a cover sheet for the next FMG. Bring to July's FMG meeting.</p>	
9.	<p><u>Drug Safety Update</u></p> <p><u>Yellow Fever Vaccine</u> – fatal adverse reactions for those whom are sixteen and over. Two incidents of this have been reported.</p>	

Notes of the Formulary Management Group

	<p><u>Valproate</u> – serious harms in pregnancy. C queried how Walsall was getting on with the Pregnancy Prevention Programme and if there is any national data or dashboard to report to. PA advised that assurance had been asked for by the Hospital and that this has been given. PCP mentioned that within Practices, the EMIS update has a prompt which requires completion before the issuing of the product. Discussions were had as to whether this feeds back to a database.</p> <p><u>Pregabalin</u> – risk of abuse. This has already been discussed as quantities have been restricted as it is now a controlled drug.</p>	
10.	<p><u>Regional Medicines Optimisation Committee</u></p> <p><u>Polypharmacy</u> – C to bring update back to July FMG meeting.</p> <p><u>Newsletter</u> – RMOC guidelines are currently being worked on for Sodium Oxabate. Homely Remedies have already been adopted.</p>	
11.	<p><u>Horizon Scanning</u></p> <p>This was not discussed during the meeting.</p>	
12.	<p><u>Appeals</u></p> <ul style="list-style-type: none"> • None 	
13.	<p><u>Formulary Breach</u></p> <ul style="list-style-type: none"> • None 	
14.	<p><u>Recommendations to JMMC</u></p> <ul style="list-style-type: none"> • None 	
15.	<p><u>Any other business</u></p> <p><u>KINES Updates</u> - C asked the committee to read the updates on the KINES.</p> <p><u>Interface Work Stream</u> – working towards QIPP efficiencies with the Trust. STP Level and new items with trials being completed. Working to make completions smoother.</p> <p><u>NHS.net Email Accounts</u> – we are now following guidance of using NHS.net emails to contact committee members.</p> <p><u>Clinical Guidelines</u> – PA2 alongside MOP advised this is now being updated but it is just awaiting clinical information. Yellow guidelines are suggested to be dissolved.</p> <ul style="list-style-type: none"> • Epipen/Adrenaline – remove. Need information on further guidance. Link any national guidance for prescribing. • DWMH Guidance Melatonin in Children – This information is already in the ESCA on net formulary. ESCA to be updated when due. Guidance to be dissolved. • Combined Hormonal Contraception checklist– remove. This can be linked to national guidance if available. • Coeliac Disease – remove. Link these to NICE guidelines. Action: GP to check with GI consultant as to whether there are any guidelines for coeliac. • Mouth care formulary – There is already a link to the guidelines. Remove. • Travel vaccines – remove. To replace with national travel guidance. 	

Notes of the Formulary Management Group

	<ul style="list-style-type: none"> • BAD Specials – discussion as to whether this should be left or removed. Links have been updated, so it has been agreed to remain. <p>Action: FP to review Trust Guidelines and provide PA2 with an update.</p> <p>Action: To be brought back as an agenda item to August FMG Meeting to discuss updates further.</p>	
16.	<p>These minutes are a true representation of the Group’s proceeding</p> <p>Signed: _____ Chair _____ Date _____</p>	

These minutes will be redacted to remove names/initials before publication

Future Meeting Dates

2019								
Formulary Management Group Future Meeting Schedule								
12:30pm Start (Finish 2:30pm)								
Date	Month	Year	Venue		Date	Month	Year	Venue
8 th	January	2019	Board Room		2 nd	July	2019	Board Room
5 th	February	2019	Room 3		6 th	August	2019	Board Room
5 th	March	2019	POD		3 rd	September	2019	Board Room
2 nd	April	2019	Board Room		1 st	October	2019	Board Room
7 th	May	2019	Board Room		5 th	November	2019	Board Room
4 th	June	2019	Board Room		3 rd	December	2019	Board Room